UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). (12th June 2019) - Tam, C.S.; Wang, M.; Simpson, D.; Opat, S.; Cull, G.; Munoz, J.; Phillips, T.J.; Kim, W.; Atwal, S.; Wei, R.; Huang, J.; Elstrom, R.; et al.